# GSK third quarter 2026 financial performance

> Developing situation record from CLSTR: https://clstr.news/situations/gsk-third-quarter-2026-financial-performance
> Updated: 2026-11-02T01:02:33.000Z. Sources: 12. Developments: 2.

GSK reported third quarter revenue of £8.9 billion, representing a 5% increase at constant exchange rates. This growth was primarily driven by the Specialty Medicines division, which saw a 23% rise in oncology sales and a 10% increase in HIV treatments. 

However, the company experienced a 16% decrease in total operating profit, falling to £2.1 billion. This decline was attributed to £328 million in restructuring costs associated with the ‘Accelerate Growth’ program, a three year initiative intended to reallocate resources toward R&D and generate annual savings of £1.9 billion by 2029. 

While core operating profit rose by 5% to £3.1 billion, exceeding analyst expectations, the vaccine segment saw a 2% decline in sales. Specific decreases were noted in the shingles vaccine Shingrix and the RSV vaccine Arexvy, partly due to reduced demand in the United States and China.

## Timeline

### 2026-11-02: GSK reports 4% revenue growth in third quarter 2026

GSK reported Q3 2026 revenue of 8.9 billion pounds, a 4% increase driven by Specialty Medicines, despite restructuring costs impacting total operating profit.

3 sources. https://clstr.news/cluster/gsk-reports-4-revenue-growth-in-third-quarter-2026

### 2026-10-27: GSK reports Q3 revenue growth driven by specialty medicines

GSK's Q3 revenue rose 5% to £8.9 billion, led by oncology and HIV drugs, despite a decline in vaccine sales and restructuring costs impacting total operating profit.

9 sources. https://clstr.news/cluster/us-employers-reduce-glp-1-weight-loss-coverage-for-2027

---
Cite as: GSK third quarter 2026 financial performance. CLSTR, https://clstr.news/situations/gsk-third-quarter-2026-financial-performance